

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6863640

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
XYNOMIC PHARMACEUTICALS, INC.	08/13/2021
RECEIVING PARTY DATA	
Name:	XYNOMIC PHARMACEUTICALS (NANJING) CO., LTD.
Street Address:	3RD FLOOR, BUILDING 02, LIFE SCIENCE AND TECHNOLOGY ISLAND
Internal Address:	11 YAOGU AVENUE, JIANGBEI NEW DISTRICT
City:	NANJING
State/Country:	CHINA
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	8889684
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6179565938
Email:	apsi@fr.com
Correspondent Name:	FISH & RICHARDSON P.C.
Address Line 1:	P.O. BOX 1022
Address Line 4:	MINNEAPOLIS, MINNESOTA 55402-1022
ATTORNEY DOCKET NUMBER:	44779-0003001
NAME OF SUBMITTER:	CRENA PACHECO
SIGNATURE:	/CRENA PACHECO/
DATE SIGNED:	08/13/2021
Total Attachments: 4	
source=44779-0003001 Xynomic Pharmaceuticals Inc to Nanjing Co., Ltd#page1.tif	
source=44779-0003001 Xynomic Pharmaceuticals Inc to Nanjing Co., Ltd#page2.tif	
source=44779-0003001 Xynomic Pharmaceuticals Inc to Nanjing Co., Ltd#page3.tif	
source=44779-0003001 Xynomic Pharmaceuticals Inc to Nanjing Co., Ltd#page4.tif	

ASSIGNMENT

Assignor: Xynomic Pharmaceuticals, Inc.
a corporation organized and existing under the laws of Delaware, and having a place of business at:
13029 Danielson Street, Suite 120, Poway, CA 92064, United States of America

Assignee: Xynomic Pharmaceuticals (Nanjing) Co., Ltd.
a corporation organized and existing under the laws of
People's Republic of China, and having a place of business at: 3rd Floor, Building 02,
Life Science and Technology Island, 11 Yaogu Avenue, Jiangbei New District, Nanjing,
China

Country	Patent Nos.	Issued Date	Title
United States	8,889,684	11/18/2014	AZAINDOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS
Germany	2670749	1/27/2016	AZAINDOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS
France	2670749	1/27/2016	AZAINDOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS
Great Britain	2670749	1/27/2016	AZAINDOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS
Japan	5850952	12/11/2015	AZAINDOLYLPHENYL SULFONAMIDES AS SERINE/THREONINE KINASE INHIBITORS

1. Assignor represents that it is the owner of the patents and patent applications listed above, and of all foreign and domestic patents, patent applications, including continuation-in-part applications, reissues, re-examinations, certificates of invention, and the like that derive priority from, or claim the benefit of the filing date of, the patents and patent applications listed above (the "Patents and Patent Applications") and of all new and useful inventions and improvements that are disclosed in the Patents and Patent Applications (the "Inventions"). The Patents and Patent Applications and the Inventions are collectively referred to as the "Patent Assets."
2. Assignor hereby assigns to Assignee its entire worldwide right, title, and interest in and to the Patent Assets, including the right to file and prosecute, in Assignee's name wherever so permitted by law or in the name of Assignor wherever necessary, patent applications, including corresponding and continuing applications, reissues, re-examinations, certificates of invention, and the like based on any of the Patent Assets, and to claim priority to any of the Patents and Patent Applications pursuant to the International Convention for the Protection of Industrial Property, the Patent Cooperation Treaty, the European Patent

Convention, and all other treaties of like purposes. Assignor acknowledges receipt of fair and adequate consideration for this Assignment.

3. Assignor shall, when requested by Assignee and at no cost to Assignor, (i) execute or cause to be executed all rightful oaths, assignments, and powers of attorney to Assignee or to agents and legal representatives of Assignee, and all other papers necessary and proper to carry out the intent and purpose of this Assignment, (ii) execute all papers necessary in connection with the Patents and Patent Applications, and any continuing, divisional, reissue, reexamination or other corresponding application thereof or post-grant proceeding relating thereto and to execute any separate assignment in connection with any such application as Assignee may deem necessary or expedient; and (iii) perform all affirmative acts that may be necessary to obtain a grant of a valid patent to Assignee on any of the Inventions.
4. Assignor hereby assigns to Assignee all of Assignor's right, title, and interest in and to any claims, whether known or unknown, suspected or unsuspected, of any nature, including choses in action, that Assignor has or may have against any party for infringement of the Patents and Patent Applications, and acknowledges receipt of fair and adequate consideration for this Assignment.
5. Assignor represents that Assignor has the full right to convey the interests assigned by this Assignment, and that Assignor has not executed and will not execute any agreement in conflict with this Assignment.
6. This Assignment is binding upon and inures to the benefit of the successors and assigns of the parties.

[ASSIGNMENT CONTINUES ON SIGNATURE PAGE]

The Assignor hereby executes this Assignment.

Assignor: Xynomic Pharmaceuticals, Inc.

Signature: Yinglin Xu

Date: August 13, 2021

Name: Yinglin Xu

Title: Chairman and Chief Executive Officer

Witnessed by:

Signature: Wentao Wu

Date: August 13, 2021

Print Name: Wentao Wu


Signature: Yun Zhang

Date: August 13, 2021

Print Name: Yun Zhang

The Assignee hereby acknowledges and accepts the foregoing assignment.

Assignee: Xynomic Pharmaceuticals (Nanjing) Co., Ltd.

Signature:  Date: August 13, 2021


Name: Yinglin Xu

Title: Legal Representative

Witnessed by:

Signature:  Date: August 13, 2021

Print Name: Wentao Wu

Signature:  Date: August 13, 2021

Print Name: Yun Zhang

62758837.doc